A large clinical and community study from the United States and Taiwan, China found that antiviral therapy for patients with HBV DNA ≥ 2 × 103 IU/mL reduced the risk of HCC by 77%, regardless of HBeAg, ALT, sex, age, and liver cirrhosis status or treatment medication [123]. Here, GPT is linked to cirrhosis of liver.